requirements in Annex II is critical.

For proper implementation, consider the following key aspects:

• Definition of Drug-Device Combinations: Understand what constitutes a combination product and how it is evaluated under both medicinal and medical device regulations.
• Relevant Guidelines: Familiarize yourself with guidance documents provided by regulatory authorities, including but not limited to the European Commission.
• Role of Notified Bodies: Grasp the importance of collaborating with an appropriate Notified Body for conformity assessment.

By equipping your team with a sound understanding of the regulatory framework, you set a foundation for successful compliance as you move forward in the process.

Step 2: Engage with a Notified Body

Engaging with a Notified Body is the next critical step in the Article 117 implementation plan. Notified Bodies are responsible for the conformity assessment of combination products to ensure adherence to EU regulations.

The selection of a Notified Body should be based on specific criteria including:

• Scope of Designation: Verify that the Notified Body is designated for the classification of the combination product you are developing.
• Experience and Expertise: Consider the Notified Body’s experience with similar products and their understanding of drug-device regulatory intersections.
• Communication and Responsiveness: Establish clear communication channels and responsiveness for effective collaboration throughout the evaluation process.

Upon securing a partnership with a Notified Body, initiate a pre-submission meeting to discuss your product and confirm the requirements for documentation. This collaboration outlines expectations for both parties and identifies areas requiring additional focus in your compliance strategy.

Step 3: Prepare Key Technical Documentation

Article 117 mandates that organizations prepare extensive technical documentation to support their claims and demonstrate compliance with GSPR. This documentation is often encapsulated within the Technical File and Design Dossier.

Your technical documentation must include:

• Product Descriptions: Comprehensive descriptions of the combined product, including intended use, design, principles of operation, and mode of action.
• Risk Management File: A structured file that addresses potential risks associated with the drug-device combination, referencing ISO 14971 standards for risk management.
• Performance and Safety Data: Data from preclinical and clinical studies, which may include results from pivotal trials to substantiate safety and efficacy claims.
• Labeling and Instructions for Use: Complete labeling information in accordance with the EU MDR and any specific requirements regarding drug and device elements.

Compiling this documentation requires meticulous attention to detail. Ensure that your documents are organized and easily navigable. Electronic submission through systems like EUDAMED may require you to format your documents according to specific templates provided by the Notified Body.

Step 4: Develop a Conformity Assessment Strategy

Establishing a conformity assessment strategy is fundamental to fulfilling the mandates of Article 117. This strategy lays out a roadmap indicating how the information compiled in your Technical Documentation will be submitted for review by the Notified Body.

Your strategy should include:

• Type of Conformity Assessment: Identify the appropriate assessment route—whether it falls under Annex VII, VIII, or IX of EU MDR—for your specific combination product.
• Clinical Evaluation Plan: Develop a robust clinical evaluation plan, detailing how clinical data will be generated and assessed in light of the combination product.
• Regulatory Pathway: Articulate the regulatory pathway and requirements that bridge both drug and device regulations, ensuring all necessary evaluations are outlined.

The Notified Body will expect a well-defined strategy that signifies your thorough preparation and understanding of compliance dynamics associated with drug-device combinations. Document any anticipated challenges and strategies to mitigate them as part of your submission preparation.

Step 5: Conduct a Clinical Evaluation

Conducting a clinical evaluation is a pivotal component under Article 117. It involves systematically reviewing available clinical data and literature to support the safety and effectiveness of the product.

The clinical evaluation should encompass:

• Existing Data Review: Systematically gather published literature relevant to your drug and device components, assessing their clinical performance and results.
• Clinical Trial Execution: If existing data is insufficient, consider conducting clinical trials that align with both EU regulatory expectations and Good Clinical Practice (GCP) guidelines.
• Documentation of Results: Document all findings thoroughly in the Clinical Evaluation Report (CER), which serves as a critical part of your submission.

Ensure that the CER addresses all required elements under the EU MDR, including justification for the clinical data obtained and how it supports compliance with safety and performance requirements. Regularly updating the CER is essential as new data becomes available or when significant product changes occur.

Step 6: Submission of Documentation to Notified Body

Once all prerequisites are established, prepare for the formal submission of your Technical Documentation to the Notified Body. Submissions should be comprehensive and align with the specific guidelines provided by the Notified Body.

Consider the following guidelines during submission:

• Compiling Submission Documents: Formulate a checklist encompassing all necessary documents, ensuring that nothing is overlooked.
• Format Compliance: Confirm that all documents adhere to the specified formats for electronic submissions, as required by the Notified Body.
• Communication Protocols: Maintain clear communication with the Notified Body regarding submission timelines, review process expectations, and any precursory assessments required.

The submission itself is a critical milestone. Ensure all documentation is complete and error-free to facilitate a smooth review process. Be prepared to answer queries or provide additional information as requested by the Notified Body during the assessment period.

Step 7: Participation in the Review Process

Following the submission, your team will be engaged in the review process carried out by the Notified Body. This stage is critical to achieving compliance with Article 117.

The review process typically includes several phases:

• Initial Review: An initial assessment where the Notified Body confirms if the submitted documentation is complete and fulfills the relevant regulatory requirements.
• Detailed Evaluation: A more comprehensive evaluation where the efficacy and safety data are rigorously examined.
• Feedback and Queries: Anticipate feedback that may require clarifications or additional information. Responding to queries in a timely manner demonstrates diligence and professionalism.

Engaging proactively with the Notified Body during this phase can facilitate a smoother review process. Regular updates and follow-ups can mitigate potential delays and rework that may arise from compliance issues.

Step 8: Post-Approval Commitments

Upon receiving approval, the essential work continues. Post-market surveillance and vigilance are integral to compliance with Article 117, ensuring continued safety and effectiveness of the drug-device combination once it enters the market.

Key activities include:

• Adverse Event Reporting: Establish robust systems for monitoring adverse events and reporting them as per regulatory guidelines.
• Post-Market Clinical Follow-Up (PMCF): Design a PMCF study if required by the Notified Body or to further substantiate the clinical data used in your initial application.
• Periodic Safety Update Reports (PSUR): Regularly generate PSURs that consolidate information on the safety profile of the product based on real-world data.

These actions reaffirm your commitment to regulatory compliance and product safety, significantly impacting your reputation and market success. Integral to maintaining market authorization, these ongoing activities will also inform iterative improvements to both the drug and device components of your combination product.